An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Inclusion Criteria:

Previously participated in protocol 005/05 (NCT00769704) and:

received the maximum number of talimogene laherparepvec treatment injections or cycles of GM-CSF allowable for that patient on study 005/05, or
new injectable lesion(s) appeared after previous resolution of all injectable disease while on study 005/05. New injectable lesions must have appeared within ≤ 12 months from the End of Treatment visit on the 005/05 study.
In the opinion of the investigator and the sponsor's medical monitor further treatment is warranted [e.g., those patients who do not have clinically relevant progressive disease (PDr)].
Performance status (Eastern Cooperative Oncology Group, ECOG) 0 or 1.
For patients randomized to talimogene laherparepvec only: Injectable disease (i.e. suitable for direct injection or through the use of ultrasound guidance) defined as at least 1 injectable cutaneous, subcutaneous or nodal melanoma lesion. There is no minimum size for injection.

Exclusion Criteria:

Prior Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4 toxicity related to talimogene laherparepvec of any organ system (with the exception of injection site reactions, fever and vomiting).
History of Grade 3 fatigue lasting > 1 week while on talimogene laherparepvec treatment.
History of Grade 3 arthralgia/myalgias while on talimogene laherparepvec treatment.
History of ≥ Grade 2 autoimmune reactions, allergic reactions or urticaria or other talimogene laherparepvec related non-hematological toxicities while on talimogene laherparepvec treatment that required a dose delay or discontinuation of talimogene laherparepvec therapy.
PDr while participating in study 005/05
Patient requested to be withdrawn from study 005/05 or was unable to comply with the demands of the 005/05 trial.
At the discretion of the investigator, patient was withdrawn from the 005/05 trial.